Multivariate Data Analysis and Central Composite Design-Oriented Optimization of Solid Carriers for Formulation of Curcumin-Loaded Solid SNEDDS: Dissolution and Bioavailability Assessment.
Galen IQ 981
S-SNEDDS
isomalt
multivariate data analysis
principal component analysis
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
06 Nov 2022
06 Nov 2022
Historique:
received:
11
10
2022
revised:
03
11
2022
accepted:
04
11
2022
entrez:
11
11
2022
pubmed:
12
11
2022
medline:
12
11
2022
Statut:
epublish
Résumé
The study was initiated with two major purposes: investigating the role of isomalt (GIQ9) as a pharmaceutical carrier for solid self-nanoemulsifying drug delivery systems (S-SNEDDSs) and improving the oral bioavailability of lipophilic curcumin (CUN). GIQ9 has never been explored for solidification of liquid lipid-based nanoparticles such as a liquid isotropic mixture of a SNEDDS containing oil, surfactant and co-surfactant. The suitability of GIQ9 as a carrier was assessed by calculating the loading factor, flow and micromeritic properties. The S-SNEDDSs were prepared by surface adsorption technique. The formulation variables were optimized using central composite design (CCD). The optimized S-SNEDDS was evaluated for differential scanning calorimetry (DSC), Fourier transform infrared spectroscopy (FTIR), X-ray diffraction (XRD), microscopy, dissolution and pharmacokinetic studies. The S-SNEDDS showed a particle size, zeta potential and PDI of 97 nm, -26.8 mV and 0.354, respectively. The results of DSC, XRD, FTIR and microscopic studies revealed that the isotropic mixture was adsorbed onto the solid carrier. The L-SNEDDS and S-SNEDDS showed no significant difference in drug release, indicating no change upon solidification. The optimized S-SNEDDS showed 5.1-fold and 61.7-fold enhancement in dissolution rate and oral bioavailability as compared to the naïve curcumin. The overall outcomes of the study indicated the suitability of GIQ9 as a solid carrier for SNEDDSs.
Identifiants
pubmed: 36365213
pii: pharmaceutics14112395
doi: 10.3390/pharmaceutics14112395
pmc: PMC9697677
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Pharmaceuticals (Basel). 2020 Jul 24;13(8):
pubmed: 32722238
Int J Pharm. 2022 Aug 25;624:121987
pubmed: 35878873
Carbohydr Polym. 2020 Dec 15;250:116996
pubmed: 33049905
Drug Deliv Transl Res. 2019 Aug;9(4):848-865
pubmed: 30911996
Saudi Pharm J. 2019 Sep;27(6):866-876
pubmed: 31516329
Drug Deliv. 2021 Dec;28(1):2119-2126
pubmed: 34612775
Int J Biol Macromol. 2021 Oct 31;189:744-757
pubmed: 34464640
AAPS J. 2015 Nov;17(6):1327-40
pubmed: 26276218
Curr Drug Deliv. 2018;15(7):1038-1054
pubmed: 29557742
Med Hypotheses. 2021 Sep;154:110644
pubmed: 34332209
Int J Biol Macromol. 2018 Dec;120(Pt B):1935-1943
pubmed: 30267819
Int J Biol Macromol. 2018 Dec;120(Pt B):1975-1998
pubmed: 30287378
Drug Dev Ind Pharm. 2018 Jul;44(7):1056-1069
pubmed: 29360412
Eur J Pharm Biopharm. 2009 Aug;72(3):621-5
pubmed: 19327398
Food Chem Toxicol. 2020 Oct;144:111590
pubmed: 32710995
Int J Pharm. 2022 Jan 25;612:121306
pubmed: 34813906
AAPS PharmSciTech. 2013 Sep;14(3):994-1003
pubmed: 23775389
Pharmaceutics. 2020 Dec 09;12(12):
pubmed: 33317067
Drug Dev Ind Pharm. 2020 Apr;46(4):597-605
pubmed: 32162980
Gynecol Endocrinol. 2020 Jul;36(7):582-587
pubmed: 31888395
Int J Biol Macromol. 2020 Apr 15;149:976-988
pubmed: 32018009
Front Pharmacol. 2017 May 16;8:261
pubmed: 28559844
J Alzheimers Dis. 2012;30(2):377-92
pubmed: 22426019
Crit Rev Ther Drug Carrier Syst. 2009;26(6):523-80
pubmed: 20402623
Nanomedicine. 2013 Aug;9(6):776-85
pubmed: 23347896
J Pharm Pharmacol. 2021 Mar 27;73(5):641-652
pubmed: 33772289
Life Sci. 2021 Sep 1;280:119753
pubmed: 34171379
Adv Drug Deliv Rev. 2011 May 30;63(6):456-69
pubmed: 21315781
Drug Deliv. 2017 Nov;24(1):1018-1025
pubmed: 28675315
Int J Mol Sci. 2021 Apr 25;22(9):
pubmed: 33923053
AAPS PharmSciTech. 2012 Dec;13(4):1416-27
pubmed: 23070560
Eur J Pharm Sci. 2017 Nov 15;109:297-315
pubmed: 28842349
Pharm Res. 2022 Nov;39(11):2817-2829
pubmed: 36195824
Philos Trans A Math Phys Eng Sci. 2016 Apr 13;374(2065):20150202
pubmed: 26953178
Biomed Pharmacother. 2017 Apr;88:715-720
pubmed: 28152481
Assay Drug Dev Technol. 2019 May/Jun;17(4):201-221
pubmed: 31100018
Pharmaceutics. 2019 Jul 16;11(7):
pubmed: 31315287
Int J Pharm. 2003 Feb 18;252(1-2):167-79
pubmed: 12550792
J Thorac Dis. 2015 Mar;7(3):E2-6
pubmed: 25922743
Int J Biol Macromol. 2019 Apr 1;126:427-435
pubmed: 30572047
ScientificWorldJournal. 2014 Feb 04;2014:978351
pubmed: 24688450
Molecules. 2020 Apr 08;25(7):
pubmed: 32276393
Drug Dev Ind Pharm. 2017 May;43(5):847-861
pubmed: 27648633
Int J Biol Macromol. 2021 Jul 31;183:1630-1639
pubmed: 34015408
Curr Drug Deliv. 2018;15(3):367-387
pubmed: 29219056
Eur J Pharm Biopharm. 2012 Feb;80(2):289-97
pubmed: 22119666
Molecules. 2020 Aug 18;25(16):
pubmed: 32824757
AAPS J. 2013 Jul;15(3):684-95
pubmed: 23572242
Asian J Pharm Sci. 2019 May;14(3):287-304
pubmed: 32104459
Molecules. 2020 Mar 18;25(6):
pubmed: 32197506
Drug Deliv Transl Res. 2014 Apr;4(2):171-86
pubmed: 25786731